Preparing for HIV drug resistance in the developing world

Issues in Infectious Diseases

Volumn 6, Issue , 2010, Pages 154-170

  Bennett, Diane E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955121869     PISSN: 16601890     EISSN: 16623819     Source Type: Book Series    
DOI: 10.1159/000298762     Document Type: Article

References (105)

1. Stevens W, Kaye S, Corrah T: Antiviral therapy in Africa. BMJ 2004;328:260-262.
2. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001;358:1819-1820.
3. Boston Globe, June 7, 2001, p A8.
4. Moatti JP, Spire B, and Kazatchkine M: Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. AIDS 2004;18(suppl 3):S55-S61. (Pubitemid 39037461)
5. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgois P, Bangsberg DR: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006;10:437-442. (Pubitemid 44174972)
6. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, Chalamilla G, Bangsberg DR: Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009;6:e11.
7. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerman T, De Cock K: The WHO public-health approach to antiretroviral treatment against HIV in resourcelimited settings. Lancet 2006;368:505-510. (Pubitemid 44142772)
8. World Health Organization. Rapid Advice: Antiviral Therapy for HIV Infection in Adults and Adolescents. 2009 World Health Organization, Geneva, Switzerland. (Accessed December 24, 2009).
9. Médecins Sans Frontières: Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries, ed 11. 2008. www.accessmed-msf.org/fileadmin/user-upload/diseas es/hiv-aids/Untangl i ng-the-Web/Untanglingtheweb-July2008-English.pdf (accessed December 15, 2009).
10. Ford N, Wilson D, Costa CG, Lotrowska M, Kijtiwatchakul K: Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS, 2007;21(suppl 4):S21-S29. (Pubitemid 47051746)
11. Pinheiroa E, Wasanb A, Kimb JY, Leed E, Guimierd, JM, and Perriens J. Examining the production costs of antiretroviral drugs. AIDS 2006;20:1745-1752. (Pubitemid 44299366)
12. Sungkanuparph, S, Manosuthi W, Kiertiburanakul S, et al: Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-452. (Pubitemid 46147631)
13. World Health Organization: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. www.who.int/hiv/pub/guidelines/ HIVstaging150307.pdf (accessed May 1, 2009).
14. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y: National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006;20:1497-1502. (Pubitemid 44100210)
15. World Health Organization; Joint United Nations Programme on HIV/AIDS; UNICEF: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. www.who.int/hiv/pub/towards-universal- access-report-2009.pdf (accessed January 2, 2010).
16. Joint United Nations Programme on HIV/AIDS: Financial resources required to achieve universal access to hiv prevention, treatment, care and support. 2007. http://data.unaids.org/pub/Report/2007/20070925-advocacy-grne2-en.pdf (accessed October 1, 2008).
17. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA: Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008;22:2509-2515.
18. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
19. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586. (Pubitemid 26097216)
20. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG: Adherenceresistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
21. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
22. Clavel F, Race E, Mammano F: HIV drug resistance and viral fitness. Adv Pharmacol 2000;49:41-66.
23. Wei X, Ghosh S, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
24. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgois P, Bangsberg DR: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006;10:437-442. (Pubitemid 44174972)
25. Gardner EM, Burman WJ, Maravi ME, Davidson AJ: Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005;40:294-300. (Pubitemid 41533069)
26. Bautista-Arredondo S, Mane A, Bertozzi SM: Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS 2006;20:101-109. (Pubitemid 41818120)
27. Garrido C, Zahonero N, Fernandes D, Serrano D, Silva AR, Ferraria N, Antunes F, Gonzalez-Lahoz J, Soriano V, de Mendoza C: Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008;61:694-698. (Pubitemid 351321149)
28. Ivers LC, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases 2005;41:217-224. (Pubitemid 40962502)
29. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois B, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2006;353:2325-2331.
30. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie J-M, Guerin PJ, Brasher C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006;367:1335-1342.
31. Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM: Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007;44:262-267. (Pubitemid 46328341)
32. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, Musick B, Einterz R, Fife KH, Tierney WM: Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006;20:41-48. (Pubitemid 41818113)
33. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, Van Cutsem G, Ledergerber B, Boulle A: Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008;5:e148.
34. Kinoti S, Tawfik L: The Impact of HIV/AIDS on the health workforce in developing countries: background paper prepared for the World Health Organization World Health Report. 2006.
35. Orrell C: Antiretroviral adherence in a resourcepoor setting. Curr HIV/AIDS Rep 2005;2:171-176.
36. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, Bangsberg DR: Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004;36:1100-1102. (Pubitemid 38989377)
37. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR: Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-690. (Pubitemid 44200639)
38. Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, Downing R, Mermin J, Weidle PJ: Longterm experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr 2005;38:578-583. (Pubitemid 40524481)
39. Colebunders R, Kamya M, Semitala F, Castelvuovo B, Katabira E, McAdam K: Free antiretrovirals must not be restricted only to treatment-naive patients. PLoS Med 2005;2:941-943.
40. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC: Response to antiretroviral therapy in HIVinfected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006;42:252-259. (Pubitemid 43054199)
41. Bisson GP, Frank I, Gross R, Lo Re V, Strom JB, Wanga X, Mogorosi M, Gaolathe T, Ndwapi N, Friednman H, Stroma BL, Dickinson D: Out-ofpocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 2006;20:1333-1336. (Pubitemid 44030386)
42. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R: Barriers to antiretroviral adherence for patients living with HIV Infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003;34:281-288. (Pubitemid 37377361)
43. Mukherjee JS, Ivers L, Leandre F: Antiretorivral Therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr 2006;43:S123-S126. (Pubitemid 44885651)
44. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD: Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2009.
45. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007;21:965-971. (Pubitemid 46684328)
46. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendex A, Laxminarayan R: Antimicrobial resistance in developing countries. Part II. Strategies for containment. Lancet Infect Dis 2005;5:568-580. (Pubitemid 41196756)
47. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noël JM, M'Bangué M: Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 2005;41:108-111. (Pubitemid 40863752)
48. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR: Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 2009;23:1035-1046.
49. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB: Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008;5:e109.
50. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A: Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-193. (Pubitemid 47482614)
51. Bangsberg DR: Adherence, viral suppression, and resistance to antiretroviral therapy. AIDS Reader 2007;17(suppl):S11-S15.
52. Pearson CR, Micek M, Simoni JM, Matediana E, Martin DP, Gloyd S: Modified directly observed therapy to faciliate high active antiretroviral therapy adherence in Beira, Mozambique. J Acquir Immune Defic Syndr 2006;43:S134-S141. (Pubitemid 44885653)
53. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R: Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007;12:83-88. (Pubitemid 46340429)
54. Culbert H, Tu D, O'Brien DP, Ellman T, Mills C, Ford N, Amisi T, Chan K, Venis S: HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med 2007;4:794-798.
55. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, Bangsberg D, Toure H, Braitstein P, Sprinz E, Nash D, Hosseinipour M, Dabis F, May M, Brinkhof MW, Egger M: Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in Sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008;13:870-879. (Pubitemid 351813514)
56. Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N: Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006;20:1613-1619. (Pubitemid 44162403)
57. Pillay D, Kityo C, Robertson V, Lyagoba F, Dunn D, Tugume S, Hakim J, Munden P, Gilks C, Kaleebu P; DART Virology Group and Trial Team: Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of combivir/tenofovir within the DART Trial. 14th Conf Retroviruses Opportunistic Infect, Los Angeles, 2007, poster 642.
58. The ART-LINC of IeDEA Study Group: Switching to second-line antiretroviral therapy in resourcelimited settings: comparison of programmes with and without viral load monitoring. AIDS 2009;23:1867-1874.
59. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD: Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007;21:721-732. (Pubitemid 46568629)
60. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Gunthard HF, Gilks C, Pillay D: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-417.
61. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-1134.
62. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E: Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009;48:1318-1322.
63. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ: Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009;52:209-221.
64. Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B, Phiri S, Van Oosterhout J: Clinical, immunological, and virological outcomes of second-line treatment, Malawi. 16th Conf Retroviruses Opportunistic Infect, Montreal, 2009. www.retroconference.org/2009/Abstracts/35596. htm (accessed January 5, 2010).
65. Renaud-Théry F, Nguimfack BD, Vitoria M, Lee E, Perriens J: Use of antiretroviral therapy in resourcelimited countries in 2007: up-take of 2nd-line and paediatric treatment stagnant. XVII Int AIDS Conf, Mexico City, 2008, oral presentation THPDB103.
66. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R: Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007;12:753-760. (Pubitemid 47235489)
67. Johnson JA, Li J-F, Morris L, Mertinson N, Gray G, McIntyre J, Heneine W: Emergence of drug-resistant HIV-1 after intrapartum administration of singledose nevirapine is substantially underestimated. J Infect Dis 2006;192:16-23.
68. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior Ibou, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mashani L, Novitsky V, Lagakos S, and Essex M: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147. (Pubitemid 46089674)
69. Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F: Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007;36:1009-1021. (Pubitemid 350018545)
70. Mellors JW and Chow JY: Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks. Clin Infect Dis 2009;48:473-475.
71. Arrive E, Dabis F: Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Curr Opin HIV AIDS 2008;3:161-165. (Pubitemid 351322830)
72. Gray GE: Walking the tightrope in prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2008;46:622-624. (Pubitemid 351263505)
73. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L: Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006;20:995-1002.
74. Mandala J, Torpey K, Kasonde P, Kabaso M, Dirks R, Suzuki C, Thompson C, Sangiwa G, Mukadi YD: Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Public Health, 2009;9:314.
75. World Health Organization: Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2009. www.who.int/hiv/pub/arv/rapid-advice-art.pdf (accessed December 24, 2009).
76. Dao H, Mofenson LM, Ekpini R, Gilks CF, Barnhart M, Bolu O, Shaffer N: International recommendations on antiretroviral drugs for treatment of HIVinfected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007;197:S42-S55. (Pubitemid 47354183)
77. World Health Organization: Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group meeting. 2008. www.who. int/hiv/pub/paediatric/WHO-Paediatric-ART-guideline-rev-mreport-2008.pdf.
78. Calmy A: Missing ARVs for HIV/AIDS treatment in 2009. UNITAID briefing at 62nd WHA, Geneva, 2009. www.msfaccess.org/fileadmin/user-upload/diseases/hiv- aids/dr.%2520calmy%2520unitaid%2520wha%25 20briefing.pdf (accessed January 2, 2010).
79. Baggaley RF, Garnett GP, Ferguson NM: Modelling the Impact of antiretroviral use in resource-poor settings. PLoS Med 2006;3:e124-e136.
80. Blower S, Brodine E, Kahn J, McFarland W: The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005;19:1-14. (Pubitemid 40111013)
81. Vardavas R, Blower S: The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. PLoS ONE, 2007;2:e152.
82. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-2011. (Pubitemid 37548427)
83. DART Virology Group and Trial Team: Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-1399.
84. Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, et al: Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004;37:1581-1583. (Pubitemid 39658197)
85. Cornman DH, Kiene SM, Christie S, Fisher WA, Shuper PA, Pillay S, Friedland GH, Thomas CM, Lodge L, Fisher JD: Clinic-based intervention reduces unprotected sexual behavior among HIVinfected patients in KwaZulu-Natal, South Africa: results of a pilot study. J Acquir Immune Defic Syndr 2008;48:553-560.
86. Bunnell R, et al: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006;20:85-92. (Pubitemid 41818118)
87. Bunnell R, Mermin J, DeCock KM: HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA 2006;296:855-858. (Pubitemid 44223108)
88. World Health Organization and Joint United Nations Program on HIV/AIDS: Guidance on provider-initiated HIV Testing and counseling in health facilities. 2007. http://whqlibdoc.who.int/publications/2007/9789241595568-eng.pdf (accessed January 5, 2009).
89. Little SJ, Dawson K, Hellman NS, Richman DD, Frost SDW: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Antiviral Ther 2004;8:S129-S129.
90. Pao D, Andrady U, Clarke J, et al: Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004;37:1570-1573. (Pubitemid 39658194)
91. Hue S, Gifford RJ, Dunn D, Fernhill E, Pillay D: Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009;83:2645-2654.
92. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Ther 2008;13(suppl 2):1-13. (Pubitemid 352019085)
93. Jordan MR, Bennett DE, Bertagnolio S, Sutherland D, Gilks C: World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antiviral Ther 2008;13(suppl 2):15-23. (Pubitemid 352019086)
94. Myatt M, Bennett DE: Development of a novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antiviral Ther 2008;13(suppl 2):19-37.
95. Bennett DE, Myatt M, Sutherland D, Bertagnolio S, Gilks CF: Recommendations for surveillance of transmitted hiv drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther 2008;13(suppl 2):25-36. (Pubitemid 352019087)
96. Ndembi N, Lyagoba R, Nanteza B, Kishemererwa G, Serwanga J, Katongole-Mbidde E, Grosskuth H, Kaleebu P: Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses 2008;24:889-895. (Pubitemid 351871676)
97. Laurent C, Kouanfack C, Koulla-Shiro S, et al: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1 infected adults in Cameroon: openlabel multicentre trial. Lancet, 2004;364:29-34. (Pubitemid 38968622)
98. UNITAID: UNITAID approves patent pool. 2009. www.unitaid.eu/en/ 20091215237/News/UNITAIDAPPROVES-PATENT-POOL.html (accessed January 19, 2010).
99. Nachega J, Stein DM, Lehman DA, et al: Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Hum Retroviruses 2004;20:1053-1057.
100. Dlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, Greeff M, Naidoo J, Mullan J, Uys LR, Holzemer WL: HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS 2009;23:377-387.
101. Liamputtong P, Haritavorn N, Kiatying-Angsulee N: HIV and AIDS, stigma and AIDS support groups: perspectives from women living with HIV and AIDS in central Thailand. Soc Sci Med 2009;69:862-868.
102. Jha CK, Madison J: Disparity in health care: HIV, stigma, and marginalization in Nepal. J Int AIDS Soc 2009;12:16.
103. Gamper A, Nathaniel S, Robbe IJ: Universal access to antiretroviral therapy and HIV stigma in Botswana. Am J Public Health 2009;99:968-969.
104. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S: Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006;43:501-503. (Pubitemid 44737112)
105. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C: Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006;58:637-644. (Pubitemid 44288131)